Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting
- PMID: 1833888
- DOI: 10.1177/106002809102500408
Ondansetron: a serotonin receptor (5-HT3) antagonist for antineoplastic chemotherapy-induced nausea and vomiting
Abstract
Ondansetron represents a new class of drugs that exert their antiemetic activity by selective inhibition of a serotonin receptor subtype (5-HT3). Ondansetron has marked activity against emesis associated with cisplatin and other highly emetogenic drugs. Compared with high doses of metoclopramide, the antiemetic "gold standard," it demonstrates equal or superior efficacy. Although ondansetron is moderately well absorbed after oral administration, only a parenteral formulation will initially be available. Ondansetron is eliminated almost entirely by hepatic metabolism; less than five percent of an intravenously administered dose is recovered intact in urine. The half-life of ondansetron is approximately 3.5 hours; slightly shorter in children and prolonged in the elderly. Neither clinical efficacy nor adverse effects have correlated with serum concentrations. Ondansetron is generally well tolerated. Clinically relevant adverse effects include headache, diarrhea or constipation, sedation, and transient minor elevations of liver function tests. It is not associated with extrapyramidal reactions. Ondansetron is indicated as prophylaxis for nausea and vomiting associated with emetogenic chemotherapy. Studies to further evaluate and define its use are ongoing.
Similar articles
-
[Recent improvements in antiemetic therapy].Tumori. 1997;83(2 Suppl):S3-14. Tumori. 1997. PMID: 9235727 Review. Italian.
-
Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.Drugs. 1994 Nov;48(5):761-93. doi: 10.2165/00003495-199448050-00008. Drugs. 1994. PMID: 7530631 Review.
-
Ondansetron. Therapeutic use as an antiemetic.Drugs. 1991 Apr;41(4):574-95. doi: 10.2165/00003495-199141040-00006. Drugs. 1991. PMID: 1711961 Review.
-
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.Drugs. 1993 Jun;45(6):931-952. doi: 10.2165/00003495-199345060-00006. Drugs. 1993. PMID: 7691500 Review.
-
Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.Semin Oncol. 1992 Aug;19(4 Suppl 10):41-7. Semin Oncol. 1992. PMID: 1387249 Review.
Cited by
-
Ondansetron-induced pseudoallergy with non-ischemic myocardial injury: A rare case report of Kounis syndrome.Clin Case Rep. 2022 Dec 22;10(12):e6781. doi: 10.1002/ccr3.6781. eCollection 2022 Dec. Clin Case Rep. 2022. PMID: 36578798 Free PMC article.
-
Prescribed drugs containing nitrogen heterocycles: an overview.RSC Adv. 2020 Dec 15;10(72):44247-44311. doi: 10.1039/d0ra09198g. eCollection 2020 Dec 9. RSC Adv. 2020. PMID: 35557843 Free PMC article. Review.
-
All Roads Lead to the Gut: The Importance of the Microbiota and Diet in Migraine.Neurol Int. 2023 Sep 13;15(3):1174-1190. doi: 10.3390/neurolint15030073. Neurol Int. 2023. PMID: 37755364 Free PMC article. Review.
-
A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.Headache. 2021 Apr;61(4):576-589. doi: 10.1111/head.14099. Epub 2021 Apr 1. Headache. 2021. PMID: 33793965 Free PMC article. Review.
-
Improvement of hemichorea with ondansetron.Postgrad Med J. 1997 Feb;73(856):127. doi: 10.1136/pgmj.73.856.127. Postgrad Med J. 1997. PMID: 9122098 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical